Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ATIS is on the move! -- Ignore unavailable to you. Want to Upgrade?

To: John M. McCann who wrote (2150)	1/20/2001 3:15:27 AM
From: Bruce Long	Respond to of 2205

Hi Marshall, Jack, and all, Glad to see that we're all still around. Obvious who the true believers are. I was sitting in on a Cardiothoracic Grand Rounds today where the discussion was on new devices designed to simplify the process of harvesting veins. All I could do was giggle to myself thinking all this sophisticated device will be obsolete once ATIS is able provide heart vessels off the shelf - wouldn't that be great. I wonder when we'll hear more about the heart patch. There seems to be a lot of buzz right now in trying to figure out a way to deliver angiogenic factors transvenously into the endocardium. I know of a couple of people that are working with bone marrow, but they're having a lot of trouble because the catheters available appear to cause significant damage to the cells before they actually make it into the heart tissue. I wonder if ATIS may be able to shed some light on this problem having a great deal of experience in the area of shear stress and tissue cells. My feeling is that the heartpatch will likely be the best near term solution to those patients in end stage heart failure. I can't see how catheter technology will be able seed enough cells to make much of a difference, oppose to applying a patch that entirely wraps around the epicardium of the heart. Thanks Marshall for keeping us up to date on the FDA timeline. Still holding on to those shares, Bruce Long